Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Coherus Oncology Inc

CHRS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$1.42

▲ +3.65%

Market Cap $219.39M · Vol 96.30K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$219.39M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+38.93%

YoY

RSI (14)

68.00

Momentum

Beta

0.98

vs Market

52W High

$2.62

45.70% below

52W Low

$1.09

30.28% above

Volume

96.30K

Avg 272.28K

P/B

2.82

Price-to-book

ROE

448.66%

Return on equity

Free Float

78.89%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Coherus Oncology Inc (CHRS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CHRS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.71%

-4.05%

-9.84%

-19.32%

YTD

+0.00%

+8.40%

-70.96%

-90.96%

Financials & Valuation

TTM · Annual

Total Revenue	$42.17M
Net Income	$-183,124,000.00
Revenue Growth (YoY)	+39.53%
Gross Margin	67.24%
Operating Margin	-409.59%
Net Profit Margin	-434.23%
ROE	448.66%
ROA · ROIC	-51.81% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	3.94
P/B	2.82
P/FCF	N/A
EPS Growth	+38.93%
Outstanding Shares	154.50M

Technical Indicators

50-Day SMA	$1.40
200-Day SMA	$1.57
RSI (14)	68.00
Beta	0.98
52-Week High	$2.62
52-Week Low	$1.09

Volume Today	96.30K
Avg Daily Volume (30D)	272.28K
Relative Volume	0.35x
Volatility (10D)	55.59
Volatility (30D)	78.63
Free Float	78.89%

Analyst Consensus

BUY

Current Price $1.42

Mean Target $7.00

52W Low$1.09 52W High$2.62

Current

Target

$1.09 $2.62

Current Analyst target

+392.96% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0063N8V87

ISINUS19249H1032

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -0.88% JNJ Johnson & Johnson -1.15% ABBV Abbvie Inc -1.44% NVS Novartis AG -1.90% NOVN.S Novartis AG -1.33%

Company Profile

Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).